Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Coverage for ultrasound diagnostic

This article was originally published in The Gray Sheet

Executive Summary

CMS 1proposes Feb. 26 to remove national non-coverage of cardiac output Doppler monitoring, noting "there is sufficient evidence to conclude that esophageal Doppler monitoring of cardiac output for ventilated patients in the ICU and operative patients with a need for intra-operative fluid optimization is reasonable and necessary." CMS was asked to reconsider its existing non-coverage policy by UK-based Deltex Medical Group, whose CardioQ esophageal Doppler monitor was cleared by FDA in 2003 (2"The Gray Sheet" Sept. 11, 2006, p. 12). Comments on the proposal are due March 28, with a final decision expected in May...

You may also be interested in...



CardioQ covered

UK firm Deltex Medical's CardioQ esophageal Doppler monitor gets national coverage from CMS May 22. The agency's 1decision to cover Doppler monitoring of cardiac output for ventilated patients in the ICU and patients with a need for intra-operative fluid optimization during surgery mirrors CMS' earlier proposal to reverse its long-standing noncoverage policy for the procedure (2"The Gray Sheet" March 5, 2007, In Brief). The esophageal Doppler monitor competes with pulmonary artery catheters, providing real-time data on left ventricular blood flow. "Given the breadth of the coverage determination, between 5 and 10 million patients [in the U.S.] annually would benefit ... using CardioQ," Deltex CEO Andy Hill told "The Gray Sheet"...

CMS Reconsiders Medicare Coverage For Esophageal Blood Flow Monitor

CMS is reconsidering Medicare coverage for a probe that uses the Doppler effect to measure the volume of blood being pumped through the body in sedated patients

Chinese Firms Up Their Game In Novel Flu Antiviral Development

Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT024541

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel